Wed Apr 9, 2025 04:49 PM Last update on: Wed Apr 9, 2025 05:56 PM Square Pharmaceuticals PLC has received the Excellence in Investment Award 2025 under the Local Investment category at the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Two entities of Square Group -- Square Pharmaceuticals and Square Textiles ... Meanwhile, Square Textiles PLC reported a profit of Tk 25 crore in the third quarter of 2024-25, marking a 7 ...

LONDON, UNITED KINGDOM / ACCESS Newswire / April 28, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases ...

LONDON, UNITED KINGDOM / ACCESS Newswire / April 28, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces ...

DUBLIN, April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company ...

Kiniksa Pharmaceuticals International PLC (NASDAQ:KNSA) is set to release its Q1 2025 earnings on Apr 29, 2025. The consensus estimate for Q1 2025 revenue is $130.61 million, and the earnings are ...

and Square Pharmaceutical (local company) were honoured with the Excellence in Investment Award 2025. The chief adviser handed over the awards. Baroness Rosie Winterton, UK's Trade Envoy to Bangladesh ...

LONDON, GB / ACCESS Newswire / May 2, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that the second patient has been successfully treated as part of the Company's ongoing ...

DUBLIN, April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Avadel Pharmaceuticals plc has a 12 month low of $6.60 and a 12 month high of $19.09. The stock has a market cap of $657.08 million, a P/E ratio of -8.61 and a beta of 1.52.